Clinical Professor of Medicine, Beth Israel Deaconess Medical Center
Hematology
Dr. Marc B. Garnick, MD
|
|
Give Review
Dr. Marc B. Garnick is an expert in the field of Hematology. He studied medicine at Perelman School of Medicine at the University of Pennsylvania. He has 5 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Boston Herald" and "Super Doctor". Marc B. Garnick is a published doctor and has 99 publications published. The lastest was: 'Effect of phenobarbital on biliary lipid metabolism in normal man.' Dr. Marc B. Garnick is registered with Medicare.
Publications
- Reply to S. Barni et al and M. Sun et al.
- The utility of prostate-specific antigen in the management of advanced prostate Cancer.
- New treatment paradigm for prostate Cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agon...
- Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate Cancer during active surv...
- Screening and detection of breast Cancer and prostate Cancer.
- Important considerations in LHRH antagonist therapy for prostate Cancer.
- Redefining the refined retroperitoneal lymph node dissection in testis Cancer: a SWOT analysis of nonrandomized data.
- The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
- Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
- Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate Cancer.
- Effect of phenobarbital on biliary lipid metabolism in normal man.
- Letter: "Hot-watch syndrome".
- Letter: Effects of the normal menstrual cycle on human gallBladder bile.
- Long-term followup of 150 patients with testicular Cancer treated at a single institution.
- CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ Cell tumors: can residual malignancy or teratoma...
- Clinical applications of recombinant macrophage-colony stimulating factor (rhM-CSF).
- Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels.
- The role of recombinant human erythropoietin in the management of Anemia associated with acquired immunodeficiency syndrome.
- Leuprolide therapy for prostate Cancer. An association with scintigraphic "flare" on bone scan.
- Biology and management of bladder Cancer.
- Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF).
- Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates.
- Initial evaluation and response criteria for patients with superficial bladder Cancer. Report of a workshop.
- Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.
- In vivo hematologic effects of recombinant human macrophage colony-stimulating factor.
- Therapeutic guidelines and results in advanced seminoma.
- Possible benefit of doxorubicin treatment in patients with refractory germ cell Cancer.
- Cavitary Lung nodules associated with combination chemotherapy containing bleomycin.
- Management of patients with clinical stage I or II nonseminomatous germ Cell tumors of the testis. Evolving therapeutic options.
- Acute pancreatitis associated with chemotherapy for germ Cell tumors in two patients.
- Failure patterns of nonseminomatous testicular germ Cell tumors: radiographic analysis of 51 cases.
- Advanced testicular Cancer: treatment choices in the "land of plenty".
- Chemotherapy and bladder Cancer.
- Testicular Cancer.
- Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6.
- Radiation therapy of seminoma: 17-year experience at the Joint Center for Radiation Therapy.
- Psychosocial factors, curative therapies, and behavioral outcomes. A comparison of testis Cancer survivors and a control group of healthy men.
- Detection of retroperitoneal metastases in early-stage nonseminomatous testicular Cancer: analysis of different CT criteria.
- Case 48-1987: pulmonary mass of 3 1/2 years' duration.
- Late toxicities, long-term follow-up, less intensive treatment: leading issues in the therapy of testis Cancer.
- Stage I nonseminomatous germ Cell testicular tumor: prediction of metastatic potential by primary histopathology.
- Stage II nonseminomatous germ Cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease.
- Nodular pneumonitis after Cancer chemotherapy.
- Phase II trial of streptozocin in the treatment of advanced renal Cell carcinoma.
- Gonadotropin-releasing hormone analogs and prostatic Cancer.
- Hematologic malignancies associated with primary mediastinal germ-Cell tumors.
- Pulmonary emboli as a complication of germ cell Cancer treatment.
- Current status of endocrine therapy for prostate Cancer.
- Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate Cancer. Results of a prospectively randomized trial.
- Phase I/II study of recombinant interferon gamma in advanced renal Cell carcinoma.
- Silicone lymphadenopathy in a long distance runner: complication of a silastic prosthesis.
- Clinical stage I Carcinoma of the testis: a review.
- Metastatic Testicular teratoma invading the inferior vena cava.
- CT evaluation of advanced seminoma treated with chemotherapy.
- Appropriate endpoints for superficial bladder Cancer clinical trials.
- Toward more rational management for stage I testis Cancer: watch out for "watch and wait"!
- Residual abdominal masses after chemotherapy for nonseminomatous testicular Cancer: correlation of CT and histology.
- Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced Cancer of the prostate.
- Unusual behavior of low-grade, low-stage transitional Cell carcinoma of bladder.
- Curative testis Cancer therapy: psychosocial sequelae.
- The efficacy of routine whole lung tomography in germ Cell tumors.
- Testicular Cancer in a Russell-Silver dwarf.
- The spectrum of genitourinary abnormalities in patients with cryptorchidism, with emphasis on testicular Carcinoma.
- Effect of cytotoxic agents on protein kinetics in patients with metastatic Cancer.
- Pulmonary complications of chemotherapy regimens containing bleomycin.
- Pulmonary complications associated with combination chemotherapy programs containing bleomycin.
- Cancers of unknown origin: current approaches and future perspectives.
- Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for Liver metastases using an implantable infusion pump.
- Changing concepts in the treatment of nonseminomatous germ Cell tumors of the testis.
- Biochemical pharmacology in medical oncology.
- Urinary tract toxic effects of Cancer therapy.
- Acute febrile reaction to streptozocin.
- Idiopathic thrombocytopenia in association with extragonadal germ cell Cancer.
- Chemotherapy of refractory germ cell Cancer with Etoposide.
- Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion.
- Acute leukemia after radiotherapy in a patient with Turcot's syndrome. Impaired colony formation in Skin fibroblast cultures after irradiation.
- Oral metoclopramide and cisplatin chemotherapy.
- Treatment and surgical staging of testicular and primary extragonadal germ cell Cancer.
- Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder Carcinoma.
- Indwelling double-J ureteral stents for temporary and permanent urinary drainage: experience with 87 patients.
- Primary cerebral venous thrombosis in patients with Cancer--a rarely diagnosed paraneoplastic syndrome. Report of three cases and review of the literature.
- Risk factors for thyroid abnormalities after neck irradiation for childhood Cancer.
- Clinical evaluation of long-term, continuous-infusion doxorubicin.
- Iliopelvic radionuclide lymphoscintigraphy in patients with testicular Cancer.
- Phase I trial of mitoxantrone by 24-hour continuous infusion.
- Computerized tomography scan for diagnosis and staging of renal Cell carcinoma.
- Doxorubicin in pregnancy: possible transplacental passage.
- High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
- Eye toxicity of Cancer chemotherapy: a review of the literature.
- Complications of retroperitoneal lymphadenectomy in the management of nonseminomatous tumors of the testis.
- Computerized tomography: how accurate for abdominal staging of testis tumors?
- Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum.
- Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenoCarcinoma.
- Phase II trial of mitoxantrone.
- Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenoCarcinoma.
- Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.
- Testicular self-examination.
- Prostatic adenoCarcinoma, sarcoidosis and hypercalcemia: an unusual association.
Schools
University Of Pennsylvania School Of Medicine
University Penn Hospital
Dana Farber Cancer Institute
Nat39l Institute Health Bethesdamd
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Boston Herald
- Super Doctor
Education
-
University of Pennsylvania Health System -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Beth Israel Deaconess Medical Center -
Beverly Hospital
Drug Facts
| NPI NUMBER | 1861429342 | |
| NPPES Provider LastName | GARNICK | |
| NPPES Provider FirstName | MARC | |
| NPPES Provider ZIPCode | 022155400 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 136.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861429342 |
| Last Name Of The Provider | GARNICK |
| First Name Of The Provider | MARC |
| View All |
Similar Doctors
|
|
Dr. Robert F. Donnell, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Janice G. Galinsky, NP |
|
|
Dr. William A. Wood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayad Hamdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David C. Harmon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth A. Bauer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey M. Gore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart H. Orkin, MD
This Doctor is OpenDoctor Recommended.
|